Randomization and blinding
All eligible subjects will be randomly assigned (1:1) either to the finerenone or placebo group via a web-based program with dynamic allocation using a minimization method balanced by age (< 70, ≥ 70 years), sex (female, male), eGFR (< 45, ≥ 45 mL/min/1.73 mThis trial will be conducted in a double-blind manner. After randomization, the participants, attending physicians, and other individuals involved in the trial will be masked to the group allocation results until data fixation is complete. The person (HY) responsible for allocation shall open (non-blinding) the result after the database is fixed. Blinding codes will be opened only in urgent situations (e.g., when patients require appropriate medical attention due to illness, and when safety of the participants should be ensured). If opened, the principal investigator will be notified immediately, and the participant will be withdrawn from the study.